154 related articles for article (PubMed ID: 30050595)
1. Prognostic Factors and Survival in Primary Central Nervous System Lymphoma: A Population-Based Study.
Shan Y; Hu Y
Dis Markers; 2018; 2018():7860494. PubMed ID: 30050595
[TBL] [Abstract][Full Text] [Related]
2. [Different treatment regimens for primary central nervous system lymphoma:based on SEER database].
Yang CW; Ren XH; Jiang HH; Li MX; Zhao XZ; Zhu QH; Cui Y; Lin S
Zhonghua Wai Ke Za Zhi; 2021 Jan; 59(1):52-58. PubMed ID: 33412634
[No Abstract] [Full Text] [Related]
3. Primary central nervous system diffuse large B-cell lymphoma has poorer immune cell infiltration and prognosis than its peripheral counterpart.
Chang C; Lin CH; Cheng AL; Medeiros LJ; Chang KC
Histopathology; 2015 Nov; 67(5):625-35. PubMed ID: 25829022
[TBL] [Abstract][Full Text] [Related]
4. Trends in primary central nervous system lymphoma incidence and survival in the U.S.
Shiels MS; Pfeiffer RM; Besson C; Clarke CA; Morton LM; Nogueira L; Pawlish K; Yanik EL; Suneja G; Engels EA
Br J Haematol; 2016 Aug; 174(3):417-24. PubMed ID: 27018254
[TBL] [Abstract][Full Text] [Related]
5. PD1 and PDL1 expression in primary central nervous system diffuse large B-cell lymphoma are frequent and expression of PD1 predicts poor survival.
Four M; Cacheux V; Tempier A; Platero D; Fabbro M; Marin G; Leventoux N; Rigau V; Costes-Martineau V; Szablewski V
Hematol Oncol; 2017 Dec; 35(4):487-496. PubMed ID: 27966264
[TBL] [Abstract][Full Text] [Related]
6. Clinical importance of Bcl-6-positive non-deep-site involvement in non-HIV-related primary central nervous system diffuse large B-cell lymphoma.
Song MK; Chung JS; Joo YD; Lee SM; Oh SY; Shin DH; Yun EY; Kim SG; Seol YM; Shin HJ; Choi YJ; Cho GJ
J Neurooncol; 2011 Sep; 104(3):825-31. PubMed ID: 21380743
[TBL] [Abstract][Full Text] [Related]
7. Primary central nervous system lymphoma: a profile of 26 cases from Western India.
Agarwal PA; Menon S; Smruti BK; Singhal BS
Neurol India; 2009; 57(6):756-63. PubMed ID: 20139505
[TBL] [Abstract][Full Text] [Related]
8. Incidence, clinical features, treatment and outcome of primary central nervous system lymphoma in Norway.
Salvesen Haldorsen I; Aarseth JH; Hollender A; Larsen JL; Espeland A; Mella O
Acta Oncol; 2004; 43(6):520-9. PubMed ID: 15370608
[TBL] [Abstract][Full Text] [Related]
9. Increasing incidence and continued dismal outcome of primary central nervous system lymphoma in Norway 1989-2003 : time trends in a 15-year national survey.
Haldorsen IS; Krossnes BK; Aarseth JH; Scheie D; Johannesen TB; Mella O; Espeland A
Cancer; 2007 Oct; 110(8):1803-14. PubMed ID: 17721992
[TBL] [Abstract][Full Text] [Related]
10. Primary central nervous system lymphoma--a hospital based study of incidence and clinicopathological features from India (1980-2003).
Sarkar C; Sharma MC; Deb P; Singh R; Santosh V; Shankar SK
J Neurooncol; 2005 Jan; 71(2):199-204. PubMed ID: 15690139
[TBL] [Abstract][Full Text] [Related]
11. A clinicopathological study of primary central nervous system lymphomas & their association with Epstein-Barr virus.
Sharma MC; Gupta RK; Kaushal S; Suri V; Sarkar C; Singh M; Kale SS; Sahoo RK; Kumar L; Raina V
Indian J Med Res; 2016 May; 143(5):605-15. PubMed ID: 27488004
[TBL] [Abstract][Full Text] [Related]
12. Primary central nervous system lymphoma: a study of clinicopathological features and trend in western India.
Pasricha S; Gupta A; Gawande J; Trivedi P; Patel D
Indian J Cancer; 2011; 48(2):199-203. PubMed ID: 21768666
[TBL] [Abstract][Full Text] [Related]
13. Primary central nervous system lymphomas: incidence and survival in the Southern and Eastern Netherlands.
van der Sanden GA; Schouten LJ; van Dijck JA; van Andel JP; van der Maazen RW; Coebergh JW;
Cancer; 2002 Mar; 94(5):1548-56. PubMed ID: 11920513
[TBL] [Abstract][Full Text] [Related]
14. Preferential up-regulation of osteopontin in primary central nervous system lymphoma does not correlate with putative receptor CD44v6 or CD44H expression.
Yuan J; Gu K; He J; Sharma S
Hum Pathol; 2013 Apr; 44(4):606-11. PubMed ID: 23089492
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Significance of High Ki-67 Index and Histogenetic Subclassification in Primary Central Nervous System Lymphoma.
Cho U; Oh WJ; Hong YK; Lee YS
Appl Immunohistochem Mol Morphol; 2018 Apr; 26(4):254-262. PubMed ID: 27490760
[TBL] [Abstract][Full Text] [Related]
16. Expression of signal transducer and activator of transcription 3 (STAT3) in primary central nervous system diffuse large B-cell lymphoma: a retrospective analysis of 17 cases.
Vajpayee N; Hussain J; Tolocica I; Hutchison RE; Gajra A
J Neurooncol; 2010 Nov; 100(2):249-53. PubMed ID: 20446017
[TBL] [Abstract][Full Text] [Related]
17. Expression of p53, c-Myc, or Bcl-6 suggests a poor prognosis in primary central nervous system diffuse large B-cell lymphoma among immunocompetent individuals.
Chang CC; Kampalath B; Schultz C; Bunyi-Teopengco E; Logan B; Eshoa C; Dincer AP; Perkins SL
Arch Pathol Lab Med; 2003 Feb; 127(2):208-12. PubMed ID: 12562237
[TBL] [Abstract][Full Text] [Related]
18. [Clinical characteristics and prognosis of 49 newly diagnosed primary central nervous system diffuse large B-cell lymphoma].
Song J; Liu H; Shen HL; Yue LZ; Yang XJ; Song WJ; Sun CY; Yu SZ; Ding K; Wang YH; Li LJ; Yu H; Shao YY; Wang CM; Yue SY; Fu R
Zhonghua Xue Ye Xue Za Zhi; 2021 Nov; 42(11):917-922. PubMed ID: 35045653
[No Abstract] [Full Text] [Related]
19. Rituximab in primary central nervous system lymphoma-A systematic review and meta-analysis.
Schmitt AM; Herbrand AK; Fox CP; Bakunina K; Bromberg JEC; Cwynarski K; Doorduijn JK; Ferreri AJM; Illerhaus G; Issa S; Schorb E; Zucca E; Hemkens LG; Schandelmaier S; Kasenda B
Hematol Oncol; 2019 Dec; 37(5):548-557. PubMed ID: 31418878
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for intraocular involvement in patients with primary central nervous system lymphoma.
Cho BJ; Yu HG
J Neurooncol; 2014 Dec; 120(3):523-9. PubMed ID: 25119002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
